Spruce biosciences announces acceptance of abstract for presentation at the annual meeting of the endocrine society (endo 2023)

South san francisco, calif.--(business wire)---- $sprb--spruce biosciences, inc. (nasdaq: sprb), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for the 105th annual meeting of the endocrine society (endo 2023) taking place june 15-18, 2023, in chicago. in a poster presentation, the company will highlight the effect of tildacerfont on go.
SPRB Ratings Summary
SPRB Quant Ranking